Abbott Laboratories $ABT Holdings Boosted by Prime Capital Investment Advisors LLC

Key Points

• Prime Capital boosted its ABT stake 272.4% to 118,698 shares (an added 86,827 shares) worth about $14.87 million at the end of the quarter.
• Quarterly results met EPS but missed revenue: Abbott posted $1.50 EPS (in line) and $11.46B revenue (below estimates), and issued Q1 2026 guidance of $1.12–1.18 and FY2026 guidance of $5.55–5.80 EPS.
• Income and sentiment update: Abbott declared a $0.63 quarterly dividend (2.4% yield) while analysts trimmed price targets but keep an overall "Moderate Buy" consensus (average target ≈ $134.58); insiders have executed modest share sales recently.

Prime Capital Investment Advisors LLC boosted its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 272.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 118,698 shares of the healthcare product maker's stock after acquiring an additional 86,827 shares during the period. Prime Capital Investment Advisors LLC's holdings in Abbott Laboratories were worth $14,872,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Harbor Capital Advisors Inc. bought a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $27,000. Cloud Capital Management LLC bought a new stake in shares of Abbott Laboratories during the third quarter valued at approximately $29,000. Guerra Advisors Inc bought a new stake in shares of Abbott Laboratories during the third quarter valued at approximately $31,000. Delos Wealth Advisors LLC bought a new stake in shares of Abbott Laboratories during the second quarter valued at approximately $32,000. Finally, Bridge Generations Wealth Management LLC bought a new stake in shares of Abbott Laboratories during the third quarter valued at approximately $33,000. Institutional investors own 75.18% of the company's stock.

Abbott Laboratories Price Performance

NYSE ABT opened at $103.70 on Thursday. Abbott Laboratories has a 12 month low of $100.88 and a 12 month high of $139.06. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. The firm has a market capitalization of $180.61 billion, a PE ratio of 27.88, a P/E/G ratio of 1.64 and a beta of 0.79. The company's 50 day simple moving average is $109.17 and its 200 day simple moving average is $120.35.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts' consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. During the same quarter last year, the business earned $1.34 earnings per share. The business's revenue for the quarter was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.4%. Abbott Laboratories's payout ratio is 67.74%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on ABT shares. BTIG Research cut their price target on Abbott Laboratories from $140.00 to $131.00 and set a "buy" rating on the stock in a report on Tuesday, March 31st. Leerink Partners cut their price target on Abbott Laboratories from $136.00 to $119.00 and set a "market perform" rating on the stock in a report on Friday, January 30th. Evercore cut their price target on Abbott Laboratories from $138.00 to $134.00 and set an "outperform" rating on the stock in a report on Monday. Citigroup lowered their price objective on shares of Abbott Laboratories from $140.00 to $136.00 and set a "buy" rating on the stock in a research note on Wednesday, March 11th. Finally, Argus lowered their price objective on shares of Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday, January 27th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Abbott Laboratories has an average rating of "Moderate Buy" and an average target price of $134.58.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 885 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the transaction, the executive vice president owned 146,377 shares in the company, valued at approximately $16,918,253.66. The trade was a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP John A. Jr. Mccoy sold 585 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the transaction, the vice president owned 24,628 shares in the company, valued at approximately $2,846,504.24. This trade represents a 2.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,055 shares of company stock valued at $353,097 in the last 90 days. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Barclays raised its price target on ABT to $144 and keeps an “overweight” view, a bullish signal that likely helped buying interest. Abbott Laboratories price target raised by Barclays
• Positive Sentiment: Coverage highlighting Abbott as a “dividend king on sale” (value/dividend investors) increases interest from income-focused buyers given its long track record of payout consistency. A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?
• Neutral Sentiment: Several sell‑side analysts remain constructive (maintaining buy/outperform ratings) but trimmed targets modestly (Evercore to $134 from $138; BTIG similar), which is mixed news — keeps analyst support but reduces implied upside. Evercore ISI and BTIG Lower Abbott (ABT) Price Targets, Maintain Positive Ratings
• Neutral Sentiment: Analysts and media note the stock’s recent underperformance versus the broader market even as it edges up intraday — an important context for short‑term momentum traders. Abbott Laboratories stock rises Wednesday, still underperforms market
• Negative Sentiment: Goldman Sachs cut its price target sharply to $121 from $140 (still a “buy”), a downgrade in expectation that can pressure sentiment and cap near‑term gains. Goldman Sachs adjusts price target on Abbott Laboratories to $121 from $140; maintains buy rating
• Negative Sentiment: Analyses flag recent share weakness (down materially over the past 1–3 months) and fading momentum; fundamental concerns include a modest revenue shortfall in the last quarter despite EPS in line and only modest FY guidance — reasons some investors remain cautious. Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.